Antibody Information

General Information of This Antibody
Antibody ID
ANI0QRULO
Antibody Name
Epratuzumab
Brand Name
Lymphocide
Organization
Immunomedics, Inc.; UCB SA
Indication
Acute lymphoblastic leukemia; Systemic lupus erythematosus; Non-Hodgkin lymphoma;
Synonyms
AMG-412; hLL2; IMMU-HLL2; Lymphocide
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-nd
Antigen Name
B-cell receptor CD22 (CD22)
  Antigen Info 
ChEMBI ID
CHEMBL2108404
PDB ID
5vkk , 5vl3
DrugBank ID
DB04958
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEY
NQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS
    Click to Show/Hide
Heavy Chain Varible Domain
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEY
NQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS
    Click to Show/Hide
Heavy Chain Constant Domain 1
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
    Click to Show/Hide
Heavy Chain CDR 1
GYTFTSYW
    Click to Show/Hide
Heavy Chain CDR 2
INPRNDYT
    Click to Show/Hide
Heavy Chain CDR 3
ARRDITTFY
    Click to Show/Hide
Light Chain Sequence
DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTR
ESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK
    Click to Show/Hide
Light Chain Varible Domain
DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTR
ESGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK
    Click to Show/Hide
Light Chain Constant Domain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain CDR 1
QSVLYSANHKNY
    Click to Show/Hide
Light Chain CDR 2
WAS
    Click to Show/Hide
Light Chain CDR 3
HQYLSSWT
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
ADCT-602 [Phase 1/2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
R/R B-acute lymphocytic leukemia (ALL).
Administration Dosage
A 3+3 dose-escalation design was used for phase 1. ADCT-602 was initially given IV once every 3 weeks (30 ug/kg, n=3; 60 ug/kg, n=4; 90 ug/kg, n=4); based on the PK data, the administration schedule was later amended to weekly infusions (30 ug/kg, n=3; 40 ug/kg, n=4; 50 ug/kg, n=3).
Related Clinical Trial
NCT Number NCT03698552  Clinical Status Phase 1
Clinical Description
A phase 1/2 study to evaluate the safety and anti-tumor activity of ADCT-602 targeting CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Primary Endpoint
In this phase 1 study in pts with very heavily pretreated R/R B-ALL with a median of 5 prior lines of therapy and high baseline bone marrow tumor burden, single-agent ADCT-602 was well tolerated with one pt with DLT noted at the 50 mg/kg weekly dose level. Notably, all 3 pts treated at this dose level had evidence of clinical activity with 2/3 pts achieving MRD negative CR.

   Click to Show/Hide
Experiment 2 Reporting the Activity Date of This ADC [2]
Patients Enrolled
R/R B-acute lymphocytic leukemia (ALL).
Administration Dosage
A 3+3 dose-escalation design was used for phase 1. ADCT-602 was initially given IV once every 3 weeks (30 ug/kg, n=3; 60 ug/kg, n=4; 90 ug/kg, n=4); based on the PK data, the administration schedule was later amended to weekly infusions (30 ug/kg, n=3; 40 ug/kg, n=4; 50 ug/kg, n=3).
Related Clinical Trial
NCT Number NCT03698552  Clinical Status Phase 1
Clinical Description
A phase 1/2 study to evaluate the safety and anti-tumor activity of ADCT-602 targeting CD22 in patients with relapsed or refractory b-cell acute lymphoblastic leukemia.
Primary Endpoint
In this phase 1 study in pts with very heavily pretreated R/R B-ALL with a median of 5 prior lines of therapy and high baseline bone marrow tumor burden, single-agent ADCT-602 was well tolerated with no DLTs noted. Two pts achieved MRD-negative remission. Dose escalation in the weekly schedule continues and 2 additional dose levels (40 ug/kg weekly and 50 ug/kg weekly) are planned. PK data, available for 9 pts treated at every 3-week schedule [30 ug/kg, n=3; 60 ug/kg, n=4; 90 ug/kg, n=2] showed rapid clearance of antibody with mean apparent half-life of <1 day during Cycle 1. This supported transitioning ADCT-602 administration to the weekly dosing.

   Click to Show/Hide
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT03698552  Clinical Status Phase 1
Clinical Description
A phase 1/2 study to evaluate the safety and anti-tumor activity of ADCT-602 targeting CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Epratuzumab-SN38 [Phase 1]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 37 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.06 nM
High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 2 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.19 nM
Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.20 nM
High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 4 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.34 nM
Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 5 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.38 nM
Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 6 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.41 nM
Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 7 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.46 nM
Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 8 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.46 nM
Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 9 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.50 nM
High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 10 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.51 nM
Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 11 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.73 nM
Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 12 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.81 nM
Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 13 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.83 nM
Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 14 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.84 nM
High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 15 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.16 nM
Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 16 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.16 nM
Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 17 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.50 nM
High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 18 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.66 nM
Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 19 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.72 nM
Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 20 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.77 nM
Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 21 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.84 nM
Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 22 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
2.21 nM
Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 23 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
2.29 nM
Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 24 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
2.45 nM
Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 25 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
2.88 nM
Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 26 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.52 nM
High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 27 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.68 nM
Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 28 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.22 nM
Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model B acute lymphoblastic leukemia Reh cells CVCL_1650
Experiment 29 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.50 nM
Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model B acute lymphoblastic leukemia Reh cells CVCL_1650
Experiment 30 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.68 nM
Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model Adult B acute lymphoblastic leukemia RS4;11 cells CVCL_0093
Experiment 31 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.10 nM
Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 32 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.25 nM
Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 33 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.67 nM
Low CD22 expression (CD22+; Median fluorescence=16.0)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model Childhood B acute lymphoblastic leukemia 697 cells CVCL_0079
Experiment 34 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.70 nM
Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 35 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.92 nM
Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 36 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
3.20 nM
Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 37 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
3.65 nM
Low CD205 expression (CD205+; IHC 1+)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model Burkitt lymphoma MN-60 cells CVCL_1421
Epratuzumab-CL2E-SN-38 [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Efficacy Data Median survival time (MST)
42 Day
Low CD22 expression (CD22+)
Method Description
The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.15 mg/dose (2.4 g SN-38 equivalents).
In Vivo Model WSU-FSCCL CDX model
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 2 Reporting the Activity Date of This ADC [5]
Efficacy Data Median survival time (MST)
63 Day
Low CD22 expression (CD22+)
Method Description
The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.30 mg/dose (4.8 g SN-38 equivalents).
In Vivo Model WSU-FSCCL CDX model
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 3 Reporting the Activity Date of This ADC [5]
Efficacy Data Median survival time (MST)
140 Day
Low CD22 expression (CD22+)
Method Description
The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.15 mg/dose (2.4 g SN-38 equivalents) plus Veltuzumab, 35 ug/dose.
In Vivo Model WSU-FSCCL CDX model
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 4 Reporting the Activity Date of This ADC [5]
Efficacy Data Median survival time (MST) > 161 Day Low CD22 expression (CD22+)
Method Description
The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.30 mg/dose (4.8 g SN-38 equivalents) plus Veltuzumab, 35 ug/dose.
In Vivo Model WSU-FSCCL CDX model
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Revealed Based on the Cell Line Data
Click To Hide/Show 37 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.06 nM
High CD22 expression (CD22+++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 2 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.19 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.20 nM
High CD22 expression (CD22+++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 4 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.34 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 5 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.38 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 6 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.41 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 7 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.46 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 8 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.46 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 9 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.50 nM
High CD22 expression (CD22+++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 10 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.51 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 11 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.52 nM
High CD22 expression (CD22+++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 12 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.68 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model Follicular lymphoma WSU-FSCCL cells CVCL_1903
Experiment 13 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.73 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 14 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.81 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 15 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.83 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 16 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.84 nM
High CD22 expression (CD22+++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 17 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.16 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 18 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.16 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 19 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.22 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model B acute lymphoblastic leukemia Reh cells CVCL_1650
Experiment 20 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.50 nM
High CD22 expression (CD22+++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
Experiment 21 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.66 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 22 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.68 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model Adult B acute lymphoblastic leukemia RS4;11 cells CVCL_0093
Experiment 23 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.72 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 24 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.77 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 25 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
1.84 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 26 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50) . 2.10 nM Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 27 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.21 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 28 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.25 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model Mantle cell lymphoma JeKo-1 cells CVCL_1865
Experiment 29 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.29 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 30 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.45 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 31 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.67 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model Childhood B acute lymphoblastic leukemia 697 cells CVCL_0079
Experiment 32 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.88 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 33 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
2.92 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 34 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
3.65 nM
Low CD22 expression (CD22+)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model Burkitt lymphoma MN-60 cells CVCL_1421
Experiment 35 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
135.80 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 36 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
152.30 nM
Moderate CD22 expression (CD22++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 37 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Concentration (EC50)
271 nM
High CD20 expression (CD20+++)
Method Description
Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Emab-CL2E-SN38 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
77.90 nM
Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model B acute lymphoblastic leukemia Reh cells CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
135.80 nM
Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC [4]
Efficacy Data Half Maximal Effective Concentration (EC50)
152.30 nM
Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description
In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
References
Ref 1 Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial. Blood (2022) 140 (Supplement 1): 521522.
Ref 2 A Phase 1 Trial of Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia. Blood (2021) 138 (Supplement 1): 1237.
Ref 3 A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, NCT03698552
Ref 4 Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012 Jan;11(1):224-34.
Ref 5 Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012 Jan;11(1):224-34. doi: 10.1158/1535-7163.MCT-11-0632. Epub 2011 Oct 28.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.